Nancy J Butcher

List of Publications by Year
in descending order

56 papers	2,181 citations	257101 24 h-index	243296 44 g-index
70 all docs	70 docs citations	70 times ranked	3366 citing authors

#	Article	IF	Citations
1	Elevated regional cerebral blood flow in adults with 22q11.2 deletion syndrome. World Journal of Biological Psychiatry, 2023, 24, 260-265.	1.3	0
2	Effects of copy number variations on brain structure and risk for psychiatric illness: Largeâ€scale studies from the<scp>ENIGMA</scp>working groups on<scp>CNVs</scp>. Human Brain Mapping, 2022, 43, 300-328.	1.9	30
3	Assessing the impact of mental health difficulties on young peopleâ€™s daily lives: protocol for a scoping umbrella review of measurement instruments. BMJ Open, 2022, 12, e054679.	0.8	2
4	Study protocol for developing, piloting and disseminating the PRISMA-COSMIN guideline: a new reporting guideline for systematic reviews of outcome measurement instruments. Systematic Reviews, 2022, 11, .	2.5	21
5	Systematic Review: The Measurement Properties of the Childrenâ€™s Depression Rating Scaleâ^'Revised in Adolescents With Major Depressive Disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 2021, 60, 119-133.	0.3	20
6	Prioritizing Genetic Contributors to Cortical Alterations in 22q11.2 Deletion Syndrome Using Imaging Transcriptomics. Cerebral Cortex, 2021, 31, 3285-3298.	1.6	10
7	Core Outcome Sets for Medium-Chain Acyl-CoA Dehydrogenase Deficiency and Phenylketonuria. Pediatrics, 2021, 148, .	1.0	16
8	Forks in the road: Definitions of response, remission, recovery, and other dichotomized outcomes in randomized controlled trials for adolescent depression. A scoping review. Depression and Anxiety, 2021, 38, 1152-1168.	2.0	8
9	Patient and family engagement in the development of core outcome sets for two rare chronic diseases in children. Research Involvement and Engagement, 2021, 7, 66.	1.1	11
10	Genetic contributors to risk of schizophrenia in the presence of a 22q11.2 deletion. Molecular Psychiatry, 2021, 26, 4496-4510.	4.1	87
11	Development of an international standard set of patient-centred outcome measures for overall paediatric health: a consensus process. Archives of Disease in Childhood, 2021, 106, 868-876.	1.0	19
12	Establishing a core outcome set for mucopolysaccharidoses (MPS) in children: study protocol for a rapid literature review, candidate outcomes survey, and Delphi surveys. Trials, 2021, 22, 816.	0.7	3
13	Large-scale mapping of cortical alterations in 22q11.2 deletion syndrome: Convergence with idiopathic psychosis and effects of deletion size. Molecular Psychiatry, 2020, 25, 1822-1834.	4.1	122
14	Training researchers in publication science: why, what, and how. Journal of Clinical Epidemiology, 2020, 117, 165-167.	2.4	5
15	Core outcome set for children with neurological impairment and tube feeding. Developmental Medicine and Child Neurology, 2020, 62, 201-206.	1.1	12
16	Complete Sequence of the 22q11.2 Allele in 1,053 Subjects with 22q11.2 Deletion Syndrome Reveals Modifiers of Conotruncal Heart Defects. American Journal of Human Genetics, 2020, 106, 26-40.	2.6	42
17	Response to â€œTrials for depressive disorder in adolescents: the emperor's new clothes,â€•a letter to the editor by Alain Braillon, MD, PhD. Journal of Clinical Epidemiology, 2020, 128, 159-161.	2.4	0
18	Core Outcome Set Development for Adolescent Major Depressive Disorder Clinical Trials: A Registered Report. Journal of the American Academy of Child and Adolescent Psychiatry, 2020, 59, 1297-1298.	0.3	17

#	Article	IF	Citations
19	From Research to Practice: The Importance of Appropriate Outcome Selection, Measurement, and Reporting in Pediatric Mental Health Research. Journal of the American Academy of Child and Adolescent Psychiatry, 2020, 59, 497-500.	0.3	8
20	Primary outcome reporting in adolescent depression clinical trials needs standardization. BMC Medical Research Methodology, 2020, 20, 129.	1.4	19
21	Systematic scoping review identifies heterogeneity in outcomes measured in adolescent depression clinical trials. Journal of Clinical Epidemiology, 2020, 126, 71-79.	2.4	23
22	Outcome reporting recommendations for clinical trial protocols and reports: a scoping review. Trials, 2020, 21, 620.	0.7	23
23	Mapping Subcortical Brain Alterations in 22q11.2 Deletion Syndrome: Effects of Deletion Size and Convergence With Idiopathic Neuropsychiatric Illness. American Journal of Psychiatry, 2020, 177, 589-600.	4.0	55
24	Outcomes in pediatric studies of medium-chain acyl-coA dehydrogenase (MCAD) deficiency and phenylketonuria (PKU): a review. Orphanet Journal of Rare Diseases, 2020, 15, 12.	1.2	15
25	Neurodevelopmental outcome descriptions in cohorts of extremely preterm children. Archives of Disease in Childhood: Fetal and Neonatal Edition, 2020, 105, 510-519.	1.4	12
26	Guidance on development and operation of Young Personsâ€™ Advisory Groups. Archives of Disease in Childhood, 2020, 105, 875-880.	1.0	6
27	Neurocognition and adaptive functioning in a genetic high risk model of schizophrenia. Psychological Medicine, 2019, 49, 1047-1054.	2.7	14
28	Neurobiological perspective of 22q11.2 deletion syndrome. Lancet Psychiatry,the, 2019, 6, 951-960.	3.7	70
29	Counting What Counts: The Case for Harmonized Outcomes in Child and Youth Mental Health Research. Journal of the American Academy of Child and Adolescent Psychiatry, 2019, 58, 656-658.	0.3	10
30	Establishing a core outcome set for treatment of uncomplicated appendicitis in children: study protocol for an international Delphi survey. BMJ Open, 2019, 9, e028861.	0.8	15
31	Improving outcome reporting in clinical trial reports and protocols: study protocol for the Instrument for reporting Planned Endpoints in Clinical Trials (InsPECT). Trials, 2019, 20, 161.	0.7	28
32	Guidance for reporting outcomes in clinical trials: scoping review protocol. BMJ Open, 2019, 9, e023001.	0.8	8
33	Outcomes reported in randomised clinical trials of major depressive disorder treatments in adolescents: a systematic scoping review protocol. BMJ Open, 2019, 9, e024191.	0.8	6
34	Elucidating the diagnostic odyssey of 22q11.2 deletion syndrome. American Journal of Medical Genetics, Part A, 2018, 176, 936-944.	0.7	45
35	Learning best-practices in journalology: course description and attendee insights into the inaugural EQUATOR Canada Publication School. BMC Proceedings, 2018, 12, 18.	1.8	5
36	Considerations for adaptive design in pediatric clinical trials: study protocol for a systematic review, mixed-methods study, and integrated knowledge translation plan. Trials, 2018, 19, 572.	0.7	11

#	Article	IF	Citations
37	Neuropsychiatric expression and catatonia in 22q11.2 deletion syndrome: An overview and case series. American Journal of Medical Genetics, Part A, 2018, 176, 2146-2159.	0.7	25
38	Typical features of Parkinson disease and diagnostic challenges with microdeletion 22q11.2. Neurology, 2018, 90, e2059-e2067.	1.5	35
39	A mouse model of 22q11.2 deletions: Molecular and behavioral signatures of Parkinsonâ€™s disease and schizophrenia. Science Advances, 2018, 4, eaar6637.	4.7	35
40	22q11.2 deletion syndrome lowers seizure threshold in adult patients without epilepsy. Epilepsia, 2017, 58, 1095-1101.	2.6	31
41	Neuroimaging and clinical features in adults with a 22q11.2 deletion at risk of Parkinsonâ€™s disease. Brain, 2017, 140, 1371-1383.	3.7	41
42	Obesity in adults with 22q11.2 deletion syndrome. Genetics in Medicine, 2017, 19, 204-208.	1.1	60
43	Whole-genome sequencing suggests mechanisms for 22q11.2 deletion-associated Parkinsonâ€™s disease. PLoS ONE, 2017, 12, e0173944.	1.1	17
44	Fetal growth and gestational factors as predictors of schizophrenia in 22q11.2 deletion syndrome. Genetics in Medicine, 2016, 18, 350-355.	1.1	29
45	Whole-Genome Sequencing Suggests Schizophrenia Risk Mechanisms in Humans with 22q11.2 Deletion Syndrome. G3: Genes, Genomes, Genetics, 2015, 5, 2453-2461.	0.8	43
46	Movement disorders and other motor abnormalities in adults with 22q11.2 deletion syndrome. American Journal of Medical Genetics, Part A, 2015, 167, 639-645.	0.7	49
47	Practical guidelines for managing adults with 22q11.2 deletion syndrome. Genetics in Medicine, 2015, 17, 599-609.	1.1	222
48	Cognitive Decline Preceding the Onset of Psychosis in Patients With 22q11.2 Deletion Syndrome. JAMA Psychiatry, 2015, 72, 377.	6.0	196
49	Comparative mapping of the 22q11.2 deletion region and the potential of simple model organisms. Journal of Neurodevelopmental Disorders, 2015, 7, 18.	1.5	90
50	Response to clozapine in a clinically identifiable subtype of schizophrenia. British Journal of Psychiatry, 2015, 206, 484-491.	1.7	61
51	MicroRNA Dysregulation, Gene Networks, and Risk for Schizophrenia in 22q11.2 Deletion Syndrome. Frontiers in Neurology, 2014, 5, 238.	1.1	42
52	Association Between Early-Onset Parkinson Disease and 22q11.2 Deletion Syndrome. JAMA Neurology, 2013, 70, 1359.	4.5	132
53	Functional outcomes of adults with 22q11.2 deletion syndrome. Genetics in Medicine, 2012, 14, 836-843.	1.1	74
54	Different classes of input and output neurons reveal new features in microglomeruli of the adult Drosophila mushroom body calyx. Journal of Comparative Neurology, 2012, 520, 2185-2201.	0.9	84

#	Article	IF	Citations
55	Biologically inspired EM image alignment and neural reconstruction. Bioinformatics, 2011, 27, 2216-2223.	1.8	6
56	Synaptic organization in the adult Drosophila mushroom body calyx. Journal of Comparative Neurology, 2009, 517, 808-824.	0.9	96